FDA Approves First Generic Pimobendan for Management of Congestive Heart Failure in Dogs

Today the U.S. Food and Drug Administration approved Pimomedin (pimobendan) chewable tablets for the management of the signs of mild, moderate, or severe congestive heart failure in dogs due to clinical myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM). Pimomedin is indicated for use with concurrent therapy for congestive heart failure (e.g., furosemide, etc.) as appropriate on a case-by-case basis.